IRADIMED
IRADIMED's revenue rose 14.4% to $84 million in fiscal 2025. Its operating margin was 31.2%, up from 30.0% a year earlier. Free cash flow was $17 million, down 2.5%. It paid out $15 million in dividends and buybacks, 88% of free cash flow. The diluted share count rose 0.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What IRADIMED does
IRadimed makes medical devices that are safe to use in the strong magnetic field of an MRI scanner, along with the accessories, disposable parts and services that go with them. It is based in Florida and makes its products at a single facility there.
Its main product is an intravenous (IV) infusion pump system that delivers anesthesia and other fluids during MRI scans. Ordinary pumps contain magnetic and electronic parts that can interfere with an MRI or be dangerous near its magnet. IRadimed says it is the only known provider of a non-magnetic IV pump system designed for MRI procedures. Its newest pump, the MRidium 3870, was introduced in 2025, and sales of the older 3860+ will stop during 2026. It also sells a patient vital signs monitor for use during MRI scans, and a remote display unit that lets staff control the pumps from outside the scanner room.
IRadimed makes money by selling pumps and monitors, and from the proprietary IV tubing sets that must be used with them, plus service. It sells to hospitals, acute care facilities and outpatient imaging centers in the United States and through distributors elsewhere. It says its markets are very competitive.
Its biggest risks, as it describes them
- Depending on sales of its MRI-compatible IV pumps and vital signs monitors for most of its revenue.
- Relying on a few outside suppliers for certain materials and components.
- Making and storing all of its products at one facility in Florida.
- Strict medical device rules, and competition in markets that it says are mature.
- Depending on hospital buying groups and on distributors outside the United States.
Income statement
From fiscal 2016 to 2025, earnings per share grew 12.6% a year and net income 13.5% a year, as new shares raised the share count by 7% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 62 | 58 | 50 | 52 | 51 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 11.2x | 9.1x | 4.7x | 8.8x | 8.0x |
| Quick ratio | 10.5x | 8.4x | 3.9x | 7.6x | 6.8x |
Cash flow
Projections
Project IRADIMED's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of IRADIMED reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 32.2% | 35.8% | 34.9% |
| Altman Z'' | 10.86 | 15.76 | 14.84 |
| Accruals ratio | 4.2% | −6.7% | −2.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put IRADIMED side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| IRADIMED | FY25 | 14.4% | 31.2% | 20.5% | — | — | — | |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 32 | 23 | 30 | 38 | 32 | 42 | 53 | 66 | 73 | 84 |
| Revenue growth | 2.9% | −29.0% | 31.9% | 26.5% | −17.6% | 31.8% | 27.5% | 23.0% | 11.7% | 14.4% |
| Gross profit | 26 | 18 | 23 | 30 | 24 | 32 | 41 | 50 | 56 | 64 |
| Research and development | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 3 | 3 | 3 |
| Operating income | 11 | 1 | 6 | 9 | −1 | 10 | 16 | 20 | 22 | 26 |
| Net income | 7 | 0 | 6 | 10 | 1 | 9 | 13 | 17 | 19 | 22 |
| Diluted EPS (US$) | 0.60 | 0.04 | 0.52 | 0.78 | 0.11 | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 |
| Diluted shares (millions) | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
| Cash flow | ||||||||||
| Cash from operations | 9 | 3 | 7 | 10 | 6 | 11 | 10 | 14 | 26 | 25 |
| Capital expenditure | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 7 | 8 | 8 |
| Free cash flow | 9 | 3 | 7 | 10 | 5 | 11 | 9 | 6 | 18 | 17 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 13 | 14 | 15 |
| Share buybacks | 10 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 2 | 4 | 2 | 1 | 2 | 2 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 18 | 18 | 28 | 44 | 50 | 62 | 58 | 50 | 52 | 51 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 37 | 39 | 48 | 67 | 71 | 83 | 86 | 92 | 98 | 109 |
| Total liabilities | 5 | 6 | 6 | 11 | 10 | 11 | 12 | 21 | 12 | 14 |
| Shareholders' equity | 32 | 33 | 42 | 56 | 61 | 72 | 74 | 71 | 87 | 95 |
| Margins and ratios | ||||||||||
| Gross margin | 81.1% | 75.9% | 76.3% | 77.1% | 74.3% | 76.7% | 77.5% | 76.5% | 76.9% | 76.8% |
| Operating margin | 33.6% | 5.6% | 19.7% | 22.4% | −2.4% | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% |
| Net margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
| Free cash flow margin | 26.5% | 11.4% | 23.5% | 25.6% | 16.9% | 25.8% | 17.3% | 9.2% | 24.1% | 20.5% |
| Rule of 40 (growth + FCF margin) | 29.4% | −17.5% | 55.4% | 52.1% | −0.7% | 57.6% | 44.8% | 32.2% | 35.8% | 34.9% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 22.6% | 1.5% | 16.8% | 19.8% | 2.3% | 14.0% | 17.6% | 23.7% | 24.3% | 24.8% |
| Return on assets | 19.9% | 1.3% | 14.4% | 16.7% | 2.0% | 12.1% | 15.2% | 19.4% | 20.2% | 21.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |